6W7-39333-22240
4 vaccinations
3 coded responses
50 check-ins
1 free-text entry
2 call cases
- Sex
- Female
- Age at first dose
- 31-35
- ZIP prefix
- 991 / WA
- Registered
- 2021-04-10
- Relationship
- Self
- Race
- White
- Ethnicity
- Not Hispanic or Latino
Timeline
-
2021-04-10
Registered in v-safe
-
2021-04-10
Dose 1 — Pfizer-BioNTech
- 2021-04-10
- 2021-04-11
- 2021-04-12
- 2021-04-13
- 2021-04-14
- 2021-04-15
- 2021-04-16
- 2021-04-17
- 2021-04-24
-
2021-05-01
Dose 2 — Pfizer-BioNTech
- 2021-05-01
-
2021-05-02
Health check-in — days 1–6 daily, dose 2Feeling: Fair · Site: Pain · Fever · Chills, Headache, Joint pains, Muscle or body aches, Fatigue or tirednessAdult check-in
-
2021-05-03
Health check-in — days 1–6 daily, dose 2Feeling: Fair · Site: Pain · Fever · Headache, Rash, not including the immediate area around the injection site · Be unable to workAdult check-in
-
2021-05-04
Health check-in — days 1–6 daily, dose 2Feeling: Fair · None · Be unable to work or attend schoolAdult check-in
- 2021-05-05
- 2021-05-06
- 2021-05-07
- 2021-05-08
- 2021-05-15
- 2021-05-22
- 2021-05-29
- 2021-06-05
- 2021-06-13
- 2021-07-31
- 2021-10-31
-
2021-11-19
Dose 3 — Pfizer-BioNTech
-
2021-11-20
Health check-in — days 1–6 daily, dose 3Feeling: Poor · Site: Pain · Fever · Chills, Headache, Joint pains, Muscle or body aches, Fatigue or tiredness, NauseaAdult check-in
-
2021-11-21
Health check-in — days 1–6 daily, dose 3Feeling: Fair · Site: Pain · Fever · Headache, Muscle or body aches, Fatigue or tiredness, NauseaAdult check-in
-
2021-11-22
Health check-in — days 1–6 daily, dose 3Feeling: Poor · Site: Pain · Headache, Nausea, Vomiting, Diarrhea · Be unable to work or attend schoolAdult check-in
- 2021-11-23
- 2021-11-28
- 2021-12-03
- 2021-12-10
- 2021-12-17
- 2021-12-26
- 2021-12-31
- 2022-02-18
- 2022-05-20
-
2022-10-20
Dose 4 — Pfizer-BioNTechCo-administered: Flu
- 2022-10-20
-
2022-10-21
Health check-in — days 1–6 daily, dose 4Feeling: Poor · Site: Pain · Fever · Chills, Headache, Joint pains, Muscle or body aches, Fatigue or tiredness · Be unable to work or attend schoolAdult check-in
-
2022-10-22
Health check-in — days 1–6 daily, dose 4Feeling: Fair · Site: Pain, Redness, Swelling · Fever · Headache, Joint pains, Muscle or body aches, Fatigue or tirednessAdult check-in
-
2022-10-23
Health check-in — days 1–6 daily, dose 4Feeling: Fair · Site: Pain, Redness, Swelling · Headache, Fatigue or tirednessAdult check-in
-
2022-10-24
Health check-in — days 1–6 daily, dose 4Feeling: Fair · Site: Redness · Headache, Nausea, Rash, not including the immediate area around the injection site · Be unable to work or attend schoolAdult check-in
-
2022-10-25
Health check-in — days 1–6 daily, dose 4Feeling: Fair · Site: Pain · Headache, Rash, not including the immediate area around the injection site · Be unable to work or attend schoolAdult check-in
- 2022-10-26
- 2022-11-03
- 2022-11-10
- 2022-11-17
- 2022-11-27
-
2022-12-03
Survey response — day 42, dose 4MedDRA: Respiratory syncytial virus test positive — Feeling: Poor · Be unable to work or attend school, Be unable to do your normal daily activities, Get care from a doctor or other healthcare professional · Outpatient clinic or urgent care clinic visitFree text: I tested positive for RSV.MedDRA releases: 2024-11 · check-in free text available
-
2022-12-03
Report sent to call center — day 42, dose 4Be unable to work or attend school · Be unable to do your normal daily activities · Get care from a doctor or other healthcare prOutpatient clinic or urgent care clinic visit · 1 call case(s)
- 2022-12-05
-
2022-12-05
Call successfulDoes not wish to fill out VAERS report
-
2023-01-19
Survey response — 3 months, dose 4MedDRA: Cough, Nasopharyngitis, Respiratory syncytial virus infection — Feeling: Good · Be unable to work or attend school, Be unable to do your normal daily activities, Get care from a doctor or other healthcare professional · Outpatient clinic or urgent care clinic visitMedDRA releases: 2024-11
-
2023-01-19
Report sent to call center — 3 months, dose 4Be unable to work or attend school · Be unable to do your normal daily activities · Get care from a doctor or other healthcare prOutpatient clinic or urgent care clinic visit · 1 call case(s)
- 2023-01-20
-
2023-04-20
Survey response — 6 months, dose 4MedDRA: Nasopharyngitis, SARS-CoV-2 test negative — Feeling: Fair · Be unable to work or attend schoolMedDRA releases: 2024-11
Vaccinations
| Dose | Date | Manufacturer | Co-administered |
|---|---|---|---|
| 1 | 2021-04-10 | Pfizer-BioNTech | |
| 2 | 2021-05-01 | Pfizer-BioNTech | |
| 3 | 2021-11-19 | Pfizer-BioNTech | No |
| 4 | 2022-10-20 | Pfizer-BioNTech | Flu |
Call center
| Reported | Outcome | VAERS-related outcome |
|---|---|---|
| 2022-12-03 | Successful 2022-12-05 |
Does not wish to fill out VAERS report |
| 2023-01-19 | Unsuccessful |
Free text
Release 12 — day 42, dose 4
Symptoms: I tested positive for RSV.
Each entry is dated by the survey it was written in (the CDC re-sent the releases with survey dates in 2025); click a date to see that survey response. The CDC cut some text off at about 250 characters: symptoms in every release, and the other two fields in releases 9-12. Those entries are marked "cut off by CDC".
MedDRA terms by release
| Field | Preferred term | 2021-09 | 2023-04 | 2024-11 |
|---|---|---|---|---|
| SD | Cough | · | · | ✓ |
| SD | Nasopharyngitis | · | · | ✓ |
| SD | Respiratory syncytial virus infection | · | · | ✓ |
| SD | Respiratory syncytial virus test positive | · | · | ✓ |
| SD | SARS-CoV-2 test negative | · | · | ✓ |
✓ active code · ○ coded but marked inactive · blank = not in that release